This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William R. Freeman, MD

Arch Ophthalmol. 1989;107(12):1737-1739.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In this issue of the ARCHIVES, Heinemann¹ reports the results of long-term intravitreal ganciclovir injection therapy for patients with acquired immunodeficiency syndrome (AIDS) with cytomegalovirus (CMV) retinitis. As the AIDS epidemic has grown to affect all population centers in this country, ophthalmologists have more frequently been encountering and treating patients with CMV retinitis. Recently the Food and Drug Administration approved the use of intravenous ganciclovir after reviewing a large body of reports, largely by ophthalmologists, of the efficacy of this drug in patients with AIDS with CMV retinitis. The enthusiasm for ganciclovir stems not from an extraordinarily high clinical success rate or ease of use but rather from the inexorable progression of untreated CMV retinitis, with resulting blindness.^2-4 Clinicians using ganciclovir therapy are confronted with many serious difficulties, including frequent bone marrow toxicity most commonly manifested by neutropenia (absolute neutrophil count <500 to 1000). Other difficulties include the . . . [Full Text PDF of this Article]

Author Affiliations
La Jolla, Calif

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?